Moien Kanaan, PhD
Professor, Molecular Genetics
Dean of Science and Director,
Hereditary Research Laboratory
Increasing genetic screening and advancing the understanding of inherited risk factors in diverse populations.
Genetic analysis and medical follow-up services for breast and ovarian cancer risk are among the best in the world for Jewish women in the Middle East. However, no such services existed for women of other ancestries in the same region before the Middle East Breast Cancer Study (MEBCS) was launched to address these disparities. The goals of the study, led by Drs. Moien Kanaan, Ephrat Levy-Lahad, and Mary-Claire King, are to understand the inherited breast cancer risk among Palestinian and Arab-Israeli women and to establish the necessary infrastructure for cancer genetics services for women in this population.
As a result of the MEBCS efforts, genetic testing is now routinely undertaken at most major Palestinian hospitals for women diagnosed with breast cancer. The MEBCS team has now conducted genetic testing of more than 1,400 patients of Arab ancestry, the largest cohort of Arab women in the world to undergo such testing. Drs. Kanaan, Levy-Lahad, and King have identified both common and new genetic causes of inherited breast cancer, which provides critical information about treatment and breast cancer prevention for these families and to women worldwide with the same types of mutations. The team uncovered links between mutations leading to cancer-related syndromes in children and breast and ovarian cancer in their mothers, as well as discovered a previously unknown mutation in a patient with invasive lobular breast cancer. In addition, the MEBCS has continued expanding next generation sequencing services, training scientists, and training more nurses and social workers to provide cancer genetics counseling.
The MEBCS will continue work in their core areas of focus:
Dr. Kanaan is a Professor of Molecular Genetics in the Department of Life Sciences, Faculty of Science at Bethlehem University, Palestine and Director of the Bethlehem University Hereditary Research Laboratory (HRL), which he established in 1992. Over the last 18 years, his laboratory has been investigating the genetically isolated Palestinian population and its high rate of genetically-based diseases, with a focus on hereditary hearing impairment (HHI).
Dr. Kanaan’s laboratory uses current approaches in genetics, genomics, cell biology, and biochemistry in studying inherited hearing loss in a large extended Palestinian cohort and has contributed to profiling a broad spectrum of novel mutations in many genes known to cause hearing loss. His current project with Drs. Ephrat Levy-Lahad and Mary-Claire King builds on his prior work and will focus on the mutation profiling of breast cancer in the a high–risk Palestinian population. Dr. Kanaan is recognized as a leading Palestinian geneticist. He has many publications to his credit and is a recipient of many research and scientific awards. He has participated in many international research efforts and scientific networks.
The Roslyn and Leslie Goldstein Award